Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determine the clinical activity of this compound in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanauske, A. R., Catimel, G., Aamdal, S., ten Bokkel Huinink, W., Paridaens, R., Pavlidis, N., Kaye, S. B., te Velde, A., Wanders, J., Verweij, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074418/
https://www.ncbi.nlm.nih.gov/pubmed/8562349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074418/
https://www.ncbi.nlm.nih.gov/pubmed/8562349

Ejemplares similares